Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells  by Chen, Neal X. et al.
Kidney International, Vol. 62 (2002), pp. 1724–1731
Phosphorus and uremic serum up-regulate osteopontin
expression in vascular smooth muscle cells
NEAL X. CHEN, KALISHA D. O’NEILL, DANXIA DUAN, and SHARON M. MOE
Indiana University School of Medicine, and Richard L. Roudebush Veterans Administration Medical Center,
Indianapolis, Indiana, USA
Phosphorus and uremic serum up-regulate osteopontin expres- Cardiovascular disease and stroke are the leading causes
sion in vascular smooth muscle cells. of death in patients with end-stage renal disease (ESRD),
Background. Dialysis patients have accelerated atheroscle- at a risk that is 10- to 20-fold the age- and sex-matchedrosis, with extensive calcification of both the intima and media.
general population [1]. The assessment of coronary arter-Cross-sectional studies have implicated hyperphosphatemia in
ies by new non-invasive imaging techniques such as elec-this process, but the mechanism is unclear.
Methods. To test the hypothesis that hyperphosphatemia tron beam CT scan (EBCT) has heightened the aware-
and/or uremia induces vascular calcification, bovine vascular ness that over 90% of atherosclerotic plaques observed
smooth muscle cells (BVSMC) were treated with increasing in the aging population are calcified [2]. Studies evalu-concentrations of -glycerophosphate, a phosphate donor, in
ating coronary calcification by EBCT in patients withthe presence or absence of inhibitors for sodium/phosphate
ESRD have demonstrated two- to fivefold more coro-(Na/Pi) co-transport (foscarnet) or alkaline phosphatase (leva-
misole) for 48 hours. BVSMC also were incubated for various nary artery calcification than age and sex matched indi-
times with DMEM plus 15% pooled uremic sera from patients viduals with angiographically-proven coronary artery
with low (LP) or high serum phosphorus (HP), or from pooled disease [3]. Furthermore, in a follow-up of these hemodi-healthy control serum. Calcification in BVSMC was examined
alysis patients, every patient had an increase in theirby quantitation of calcium deposition. Osteopontin expression
calcification score just one to two years later [4]. Recentand alkaline phosphatase activity were assessed by Western
blotting and a colorimetric assay. studies evaluating vascular calcification using EBCT and
Results. -glycerophosphate increased osteopontin expres- other techniques in dialysis patients have demonstrated
sion and alkaline phosphatase activity in BVSMC. Inhibition an elevated serum phosphorus value, an elevated serumof either alkaline phosphatase activity or Na/Pi co-transport
calcium X phosphorus product, or increased calcium loadabolished this effect. Compared to incubation with control
as risk factors [3, 5–7]. However, the mechanism by whichhuman serum, BVSMC cultured with uremic sera had increased
mineral deposition. Uremic sera also increased alkaline phos- the elevated concentration of these ions leads to calcifi-
phatase activity and osteopontin expression in BVSMC. The cation in dialysis patients is unknown.
addition of -glycerophosphate to uremic HP or LP sera did
Until recently, vascular calcification was considered tonot further augment osteopontin expression. Blocking Na/Pi
be a passive process. However, considerable evidenceco-transport or alkaline phosphatase activity only partially in-
hibited uremic sera-induced osteopontin expression, indicating now suggests that vascular calcification in non-dialysis
that other non-Na/Pi co-transport dependent mechanisms also patients is regulated in a manner very similar to that of
are involved. developing bone, with apatite crystal nucleation, growth,
Conclusion. -glycerophosphate and uremic sera induce cal-
and possible degradation in association with an extracel-cification and osteopontin expression in BVSMC. The uremic
lular matrix that regulates tissue mineralization (re-sera-induced osteopontin expression in BVSMC is partially
mediated through alkaline phosphatase activity and a Na/Pi viewed by Giachelli [8] and Farzaneh-Far et al [9]). In
co-transporter dependent mechanism. However, other non- dialysis patients, the presence of extra-skeletal calcifica-
Na/Pi dependent mechanisms also contribute to accelerated tion has been previously attributed to secondary hyper-
vascular calcification in patients with ESRD.
parathyroidism and metastatic calcification, whereby the
elevated concentrations of calcium and phosphorus in
the serum of dialysis patients leads to supersaturationKey words: calcification, hyperphosphatemia, uremia, intima and me-
dia, end-stage renal disease, atherosclerotic placques. and subsequent deposition in the form of hydroxyapatite.
However, we have recently demonstrated the expressionReceived for publication November 27, 2001
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and in the inferior epigastric artery of patients undergo- dialysis database, patients were identified with the fol-
ing renal transplant [7, 10]. This implies that vascular lowing: those with a mean serum phosphorus5.5 mg/dL
calcification in dialysis patients is not simply metastatic, over the preceding two years, and patients with a mean
but rather an active, cell-mediated process. serum phosphorus 6.5 mg/dL. Thirteen patients in the
We hypothesize that the uremic state leads to the de- high (6.5 mg/dL) phosphorus groups consented to have
position of these bone proteins, with subsequent, perhaps sera collected (HP). These patients were then matched
accelerated calcification, in the presence of the positive for age and presence or absence of diabetes with 14
calcium and phosphorus balance so common in ESRD patients who had phosphorus persistently 5.5 mg/dL
patients. To test this hypothesis and further clarify the (LP). Sera from normal healthy individuals of similar
molecular mechanisms regulating vascular calcification, ages served as controls. The sera were pooled and frozen
we characterized the response of bovine vascular smooth at –20C in aliquots for use in tissue culture. The pooled
muscle cells (BVSMC) to -glycerophosphate, a phos- sera were analyzed for pH by Corning pH meter 240;
phate donor, or pooled uremic sera from patients with total alkaline phosphatase, electrolytes, calcium, and phos-
persistently low versus high serum phosphorus and from phorus by chemistry autoanalyzer (Boeringer Roche Di-
pooled healthy control serum. Our results demonstrate agnostics, Indianapolis, IN, USA); parathyroid hormone
that uremic sera potentiate calcification and enhance os- (PTH) by intact assay (Nichols Laboratory, San Juan
teopontin expression in BVSMC. In addition to hyper- Capistrano, CA, USA); bone alkaline phosphatase by
phosphatemia, other uremic factors may contribute to the enzyme-linked immunosorbent assay (ELISA; Metra
accelerated vascular calcification in patients with ESRD. Biosystems, Mountain View, CA, USA); and C-reactive




Bovine VSMC were cultured in DMEM  10% FBS
Bovine vascular smooth muscle cells were obtained until confluent and then switched to calcification medium
by a modification of the explant method originally de- (DMEM containing 10 mmol/L sodium pyruvate, 107 mol/L
scribed by Ross [11]. Briefly, medial tissue was separated insulin, 50 	g/mL ascorbic acid, 100 U/mL penicillin, 100
from segments of bovine aorta after removal of endothe-
	g/mL streptomycin and 10 mmol/L -glycerophosphate),
lial cells from aorta segments. Small pieces of tissue (1 mm2) in the presence of either 15% normal human serum or 15%
were placed in a 6-well culture dish and cultured for two
uremic (HP) serum for up to 21 days. The medium wasweeks in Dulbecco’s modified Eagle’s medium (DMEM)
replaced with fresh medium every two to three days andcontaining 4.5 g/L glucose supplemented with 10% fetal
the first day of culture in calcification media was definedbovine serum (FBS; Sigma Chemical Co., St. Louis, MO,
as day 0.USA) in a 95%/5% air/CO2 humidified environment at
37C. Cells that migrated from the explants were col- Quantification of calcium deposition
lected and maintained in DMEM containing 10% FBS
Bovine VSMC were decalcified with 0.6 N HCl forsupplemented with 100 U/mL of penicillin G, 0.25	g/mL
24 hours. The calcium content of HCl supernatants wasof amphotericin B and 100 	g/mL of streptomycin. The
determined colorimetrically by the o-cresolphthalein com-media were replaced every two to three days. Only cells
plexone method (Calcium kit; Sigma) as previously de-between passages 2 and 8 were used for experiments
scribed by Jono et al [13]. After decalcification, the cells[12]. To examine the role of phosphorus in osteopontin
were washed three times with PBS and solubilized withexpression, BVSMC were treated with various concen-
0.1 N NaOH/0.1% sodium dodecyl sulfate (SDS). Thetrations of -glycerophosphate, a phosphate donor, in
protein content was measured by a DC protein assay kitthe presence or absence of an inhibitor for sodium/phos-
(Bio-Rad, Richmond, CA, USA). The calcium contentphate (Na/Pi) co-transport (foscarnet, 1 mmol/L; Sigma)
of the cell layer was normalized to protein content.or alkaline phosphatase (ALP; levamisole, 100 	mol/L;
Sigma) for 48 hours. In order to determine whether ure-
Western blot analysismic factors further contribute to accelerated vascular
Bovine VSMC were grown in a 6-well culture platecalcification in dialysis patients, BVSMC were incubated
and incubated with various reagents for 48 hours. Cellsfor 2, 3, 7, 10 and 14 days with DMEM plus 10% sera
were then washed with cold phosphate-buffered salinefrom pooled uremic sera from patients with persistently
(PBS) and incubated with ice-cold lysis buffer containinglow or high serum phosphorus and from pooled healthy
5 mmol/L HEPES (pH 7.9), 150 mmol/L NaCl, 26%control serum as described below.
glycerol (vol/vol), 1.5 mmol/L MgCl2, 0.2 mmol/L ethyl-
Collection of pooled uremic and control sera enediaminetetraacetic acid (EDTA), 0.5 mmol/L dithi-
othreitol (DTT), and 0.5 mmol/L phenylmethylsulfonylUremic and control sera were pooled from patients
who were on dialysis for at least two years. Utilizing our fluoride (PMSF). Whole cell lysates (20 	g) were mixed
Chen et al: Uremic sera and osteopontin expression1726
with equal volume of 4
 Laemmli sample buffer. The
mixture and pre-stained molecular weight markers were
boiled for five minutes and separated by 10% SDS-poly-
acrylamide gel electrophoresis (SDS-PAGE). Proteins
were electrophoretically transferred to a polyvinylidene
difluoride (PVDF) membrane (Millipore Corp., Bed-
ford, MA, USA). The membrane was blocked in Tris-
buffered saline containing 5% nonfat dry milk and 0.05%
Tween-20 (TBST) for one hour, then incubated with
rabbit antibodies against osteopontin (1:1000; gift of Dr.
Larry Fisher, NIH, Bethesda, MD, USA) overnight at
4C. The membrane was washed with TBST buffer and
then incubated with goat anti-rabbit IgG peroxidase con-
jugate (1:5000 dilution). The immunodetection was ac-
complished using the Enhanced Chemiluminescence Kit Fig. 1. Western blot analysis of -glycerophosphate (GP)-induced
(NEN Life Science Products, Boston, MA, USA). The osteopontin expression in bovine vascular smooth muscle cells (BVSMC).
Cells were treated with 4 to 12 mmol/L of -glycerophosphate (GP)band intensity was analyzed by scanning densitometry
for 48 hours. Cells were lysed and Western blotting was performed using(Molecular Analysis; Bio-Rad). osteopontin antibody. The band intensity was analyzed by scanning
densitometry. Data are shown as mean  SD from three experiments.
Alkaline phosphatase and phosphorus ion assays Groups with * are different from controls (P  0.05).
For cellular alkaline phosphatase activity measure-
ments, cells were washed three times with PBS and cellu-
lar proteins solubilized with 1% Triton X-100 in 0.9%
formed. As shown in Figure 1,-glycerophosphate inducedNaCl and centrifuged. Supernatants were assayed for
osteopontin expression in a dose dependent manner. Whilealkaline phosphatase activity as described previously by
treatment of cells with 4 mmol/L -glycerophosphateBessey and Brock [14]. One unit was defined as the
had little effect on osteopontin expression, 8 mmol/Lactivity producing 1 nmol of p-nitrophenol for 30 min-
-glycerophosphate induced a detectable increase in os-utes. Protein concentrations were determined with a Bio-
teopontin expression. The transport of phosphorus intoRad protein assay kit (Bio-Rad), and alkaline phospha-
cells is mediated through the Na/Pi co-transporter; thus,tase activity normalized to cellular protein content.
we next examined the role of Na/Pi co-transporter onPhosphorus concentration in the culture media was
osteopontin expression. BVSMC were incubated withmeasured prior to addition to BVSMC and after 48 hours
of incubation by the phosphomolybdate complex method phosphonoformic acid (foscarnet), a competitive inhibi-
(phosphorus kit; Sigma). tor of Na/Pi co-transporter, in the presence or absence of
12 mmol/L -glycerophosphate for 48 hours. The results
Statistical analysis show that foscarnet completely inhibits the induction of
The difference of alkaline phosphatase activity levels osteopontin in response to -glycerophosphate as dem-
in response to various reagents was compared by analysis onstrated by Western blotting (Fig. 2). This suggests that
of variance (ANOVA) with Fisher’s post-hoc analysis. Na/Pi co-transport is necessary for phosphorus-induced
Statistical significance of difference in expression of os- osteopontin expression in BVSMC. To confirm the im-
teopontin and calcium deposition was performed by portance of alkaline phosphatase, which can cleave -glyc-
one-way ANOVA. Comparisons were made between erophosphate into free phosphorus, in the phosphorus-
densitometric analyses of Western blots of treated and induced osteopontin expression in BVSMC, cells were
control cells. The results are expressed as mean  SEM, treated with levamisole, a specific inhibitor of alkaline
with P  0.05 considered significant (StatView; SAS
phosphatase in the presence of -glycerophosphate.Institute, Inc., Cary, NC, USA).
Western blotting showed that inhibition of alkaline phos-
phatase activity by levamisole abolished -glycerophos-
RESULTS phate-induced osteopontin expression in BVSMC (Fig. 2).
This indicated that hydrolysis of -glycerophosphate byPhosphorus-induced osteopontin expression and the
induction is dependent on Na/Pi co-transport and alkaline phosphatase is required for its induction of os-
alkaline phosphatase activity teopontin expression in BVSMC. To further clarify the
role of alkaline phosphatase in osteopontin expression inWe first examined the effect of phosphorus on osteo-
response to -glycerophosphate, we measured alkalinepontin expression by incubating BVSMC with increas-
phosphatase activity in BVSMC. -glycerophosphate in-ing concentrations of -glycerophosphate for 48 hours.
Cell lysate was extracted and Western blotting was per- creased alkaline phosphatase activity by threefold and
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Fig. 3. Alkaline phosphatase (ALP) activity in BVSMC treated with
-glycerophosphate (GP) in the presence or absence of various inhibi-
Fig. 2. Western blotting of osteopontin expression in BVSMC treated tors. Cells were treated with -glycerophosphate (GP, 12 mmol/L) in
with -glycerophosphate (GP) in the presence or absence of various the presence or absence of inhibitors for Na/Pi co-transporter (foscar-
inhibitors. Cells were treated with -glycerophosphate (GP, 12 mmol/L) net) or alkaline phosphatase activity (levamisole) for 48 hours. Cellular
in the presence or absence of inhibitors for Na/Pi co-transporter (foscar- proteins were solubilized with 1% Triton X-100 in 0.9% NaCl and su-
net) or alkaline phosphatase activity (levamisole) for 48 hours. Cells pernatants were assayed for alkaline phosphatase activity. One unit
were lysed and Western blotting performed using osteopontin antibody. was defined as the activity producing 1 nmol of p-nitrophenol for 30
The band intensity was analyzed by scanning densitometry. Data are minutes. Alkaline phosphatase activity was normalized to cellular pro-
shown as mean SD from three experiments. Groups with * are differ- tein content. Data are shown as mean  SD from three to four experi-
ent from controls (P  0.05). ments. Groups with * are different from controls (P  0.05).
Table 1. Results of analysis of pooled serathe induction of alkaline phosphatase activity by -glyc-
erophosphate was inhibited when cells were treated with Uremic sera
an inhibitor of Na/Pi co-transport (foscarnet; Fig. 3).
Control Low High
As expected, levamisole, a specific inhibitor for alkaline sera phosphate phosphate
phosphatase also abolished the increase in alkaline phos- Number of patients 14 14 13
phatase activity in response to -glycerophosphate in Age years 48.7 50.2 46.2
Gender % female 36 36 46BVSMC (Fig. 3). Thus, -glycerophosphate-induced os-
Years on HD 6.5 6.9teopontin expression in BVSMC is indeed dependent on % Diabetic 21 23
Na/Pi co-transport and alkaline phosphatase activity. % on Vitamin D 64 23
Kt/V 1.55 1.45
Na meQ/L 142 141 140Uremic serum increased calcium deposition and
K meQ/L 4.3 4.8 5.1
osteopontin expression in BVSMC and inhibition Albumin g/L 4.8 4.2 4.0
pH 8.05 8.37 8.15of Na/Pi co-transport partially blocked the
Calcium mg/dL 9.4 9.4 8.3effect of uremia
Phosphate mg/dL 3.5 5.5 7.4
PTH pg/mL 28 266 496To determine if uremia contributes to accelerate vas-
Total alkaline phosphatase IU 62 126 155cular calcification, the effect of uremic sera on calcifica-
Bone alkaline phosphatase IU 11.3 24.3 40
tion of BVSMC cultures was examined. The analysis of C-reactive protein lg/mL 0.004 0.086 32.4
the sera is given in Table 1. As expected, compared to
control serum, the uremic sera had elevated levels of
phosphorus, parathyroid hormone, total and bone alka-
line phosphatase, and C-reactive protein. In the presence 48 hours of incubation (Pre-Post). Results showed that
of uremic sera plus calcification medium, calcium deposi- pre-post values of phosphorus were 0.30 to 0.25 mmol/L
tion significantly increased in a time-dependent manner for DMEM with 10% FBS; 0.22 to 8.55 mmol/L for
in BVSMC, as compared to cells treated with normal hu- DMEM with 10% FBS plus 10 mmol/L -glycerophos-
man serum plus calcification medium (Fig. 4). This in- phate; 0.58 to 0.46 mmol/L for DMEM with 10% normal
dicates that uremic serum potentiates calcification in human serum; 0.69 to 9.67 mmol/L for DMEM with
BVSMC. 10% FBS plus 12 mmol/L -glycerophosphate; 0.67 to
To examine the phosphorus levels in the cultured me- 0.60 mmol/L for DMEM with 10% uremic serum; and
dia of BVSMC as a result of addition of -glycerophos- 0.87 to 10.45 mmol/L for DMEM with 10% uremic serum
phate, the inorganic phosphorus concentration was mea- plus 12 mmol/L-glycerophosphate. Thus,-glycerophos-
phate was converted by cells to inorganic phosphorus insured in media before its addition to BVSMC, and after
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Fig. 5. Western blotting of osteopontin expression in BVSMC treated
with uremic sera. Cells were incubated in the presence of pooled seraFig. 4. Effects of uremic serum on calcium deposition in BVSMC.
from controls, uremic high phosphorus (HP) or uremic low phosphorusAfter confluence, BVSMC were incubated with calcification media in
(LP) for 48 hours. To determine the role of Na/Pi co-transport in thethe presence of either 15% normal human serum () or 15% uremic
uremic response, cells were treated with HP in the presence of inhibitorserum () for up to 21 days. The medium was changed every 2 to 3
of Na/Pi co-transport (foscarnet) for 48 hours. Cells were lysed anddays. The calcium content was measured at the indicated times by
Western blotting was performed using osteopontin antibody. The bando-cresolphthalein complexone method, normalized by cellular protein
intensity was analyzed by scanning densitometry. Data are shown ascontent, and are presented as meanSD. Groups with * are significantly
mean  SD from three experiments. Groups with * and # are differentdifferent between normal and uremic treated cells.
from controls and different between groups (P  0.05).
DMEM with FBS, normal human serum and uremic
(Fig. 6B). These results again suggest that increased alka-serum. In addition, when diluted to 10% sera, the final
line phosphatase activity and Na/Pi co-transporter arephosphorus concentration in uremic sera was not differ-
only partially responsible for uremic sera-induced osteo-ent from that in the control serum groups.
pontin expression in BVSMC. To determine if the effectsTo test whether up-regulation of osteopontin is due
of phosphorus are additive to uremic serum, we incu-to elevated phosphorus and/or other uremic factors, we
bated BVSMC with control, uremic low phosphorus orincubated BVSMC in the presence of pooled sera from
high phosphorus sera plus 12 mmol/L -glycerophosphatehealthy volunteers or dialysis patients with low or high
and osteopontin expression analyzed by Western blot-phosphorus. As shown in Figure 5, BVSMC treated with
ting. There was no additive effect of -glycerophosphateuremic sera had increased expression of osteopontin
above that induced by uremic serum for osteopontincompared to cells treated with normal serum, suggesting
expression in BVSMC, whereas the addition of -glycer-an important role of uremic serum in vascular calcifica-
ophosphate nearly doubled osteopontin expression intion. However, there was no significant difference in os-
BVSMC incubated in control serum (Fig. 7).teopontin expression between cells treated with uremic
low phosphorus serum or uremic high phosphorus serum.
Blocking Na/Pi co-transporter with foscarnet only par-
DISCUSSIONtially inhibited uremic serum-induced osteopontin ex-
Dialysis patients are known to have many risk factorspression, indicating that in addition to Na/Pi co-transport
for vascular disease such as a history of hypertension,dependent mechanisms, there are other uremic factor(s)
diabetes, oxidized lipids, elevated homocysteine andthat may modulate osteopontin expression in BVSMC.
C-reactive protein [1, 15]. In addition to these traditionalTo further characterize the mechanism by which ure-
vascular risk factors, there is increasing evidence thatmic serum induced osteopontin expression, BVSMC
elevated serum phosphorus, serum calcium X phospho-were treated with normal serum or uremic sera with high
rus product, and/or calcium load in the form of calcium-or low phosphorus and alkaline phosphatase activity was
containing phosphate binders are associated with variousmeasured. Uremic serum doubled alkaline phosphatase
vascular end-points including coronary artery calcifica-activity in BVSMC (P 0.05; Fig. 6A), although the de-
tion by electron beam computed tomography [3], calcificgree of increase in alkaline phosphatase activity was simi-
uremic arteriolopathy (calciphylaxis) [7], carotid andlar between cells treated with high phosphorus uremic
aortic calcification [6, 16], hemodynamic abnormalities [5],serum and low phosphorus uremic serum. Inhibition of
and mortality (abstract; Levin et al, J Am Soc Nephrolalkaline phosphatase with levamisole also partially blocked
uremic sera-induced osteopontin expression in BVSMC 10:A1109, 1999) [17]. One potential mechanism by which
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Fig. 7. Densitometry analysis of Western blotting of osteopontin ex-
pression in BVSMC treated with uremic sera. Cells were incubated
with pooled sera from controls, uremic high phosphorus (HP) or uremic
low phosphorus (LP) in the presence () or absence () of -glycero-
phosphate (BGP, 12 mmol/L) for 48 hours. Cells were lysed and Western
blotting was performed using an anti-osteopontin antibody. The band
intensity was analyzed by scanning densitometry. Data are shown as
mean  SD from three experiments. Groups with * are different from
controls (P  0.05). There is no significant difference between uremic
groups treated with or without -glycerophosphate.
The identification of bone matrix proteins in vascular
calcification in non-uremic [18–22] and uremic individu-
als [7, 10] suggests an active process that may parallel
mineralization in bone. In bone, osteoblasts differentiate
from pluripotent cells with specific gene products at dif-
ferent stages of differentiation and mineralization. In
vitro, a model of this process, bone nodules, can be in-
duced in osteoblasts in the presence of -glycerophos-
phate and ascorbic acid. In these bone nodules, a discrete
Fig. 6. Alkaline phosphatase (ALP) activity and osteopontin expres- zone of hydroxyapatite-containing mineral is formed
sion in BVSMC treated with uremic sera. (A) Cells were incubated in
within the collagen fibrils and along the non-collagenousthe presence of pooled sera from controls, uremic high phosphorus
proteins such as osteopontin [23–25]. The-glycerophos-(HP) or uremic low phosphorus (LP) for 48 hours. Cellular proteins
were solubilized with 1% Triton X-100 in 0.9% NaCl and supernatants phate is cleaved to free phosphate by the enzyme alkaline
were assayed for alkaline phosphatase activity. One unit was defined as phosphatase for which ascorbic acid is an essential co-fac-the activity producing 1 nmol of p-nitrophenol for 30 minutes. Alkaline
tor. Alkaline phosphatase is commonly considered a phe-phosphatase activity was normalized to cellular protein content. Data
are shown as mean  SD from three to four experiments. Groups with notypic marker of osteoblasts that is critical for bone
* are different from controls (P  0.05). (B) Cells were incubated in mineralization [26]. A recent study in osteoblast MC3T3
the presence of pooled sera from controls or uremic high phosphorus
cells has further demonstrated the importance of this(HP) for 48 hours. To determine the role of alkaline phosphatase activity
in the uremic response, cells were treated with HP in the presence of enzyme in the induction of osteopontin expression [25].
an inhibitor of alkaline phosphatase (levamisole) for 48 hours. Cells Several groups have recently demonstrated that both
were lysed and Western blotting was performed using an anti-osteopon-
human and bovine VSMC also can calcify their extracel-tin antibody. The band intensity was analyzed by scanning densitometry.
lular matrix in vitro in the presence of -glycerophos-
phate and ascorbic acid, in a manner similar to osteo-
blasts [12, 27]. In vitro, these vascular smooth muscle
disordered mineral metabolism may contribute to vascu- cells produce alkaline phosphatase, type I collagen, and
lar calcification is through the regulation of the deposi- non-collagenous proteins such as osteopontin and osteo-
tion of bone matrix proteins, such as osteopontin. The calcin [12, 13], suggesting that vascular smooth muscle
present study found that the up-regulation of osteopon- cells retain their pluripotential and transform into osteo-
tin expression by -glycerophosphate, a phosphate do- blast-like cells. We have recently demonstrated the ex-
nor, is dependent on the activity of Na/Pi co-transporter pression of osteopontin, alkaline phosphatase, type I col-
and alkaline phosphatase in BVSMC. We also demon- lagen and bone sialoprotein by VSMC in arteries of
strated, to our knowledge for the first time, that uremic dialysis patients undergoing a renal transplant [10]. Fur-
serum potentiated calcification and osteopontin expres- thermore, the deposition of these “bone” proteins pre-
sion in BVSMC. The ability of uremic serum to induce cedes overt calcification, suggesting that the transforma-
osteopontin expression is associated, at least partly, with tion of VSMC to osteoblast-like cells with expression of
the Na/Pi co-transport and the activity of alkaline phos- these proteins is an essential first step. These proteins
may then regulate subsequent calcification.phatase in BVSMC.
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The mechanism by which these bone matrix proteins porting this mechanism is our recent result identifying
the expression of Cbfa1 in both the intima and mediamay regulate calcification is not completely clear. For
example, the addition of osteopontin to mineralizing of calcified arteries in areas with strong expression of
type I collagen and osteopontin (abstract; Moe, J AmBVSMC cultures inhibited calcification [28]. However,
Jono et al recently demonstrated that the phosphoryla- Soc Nephrol 12:756A, 2001). These results are exciting
and offer a potential pathophysiologic link between thetion of osteopontin was critical for this activity: non-
phosphorylated osteopontin (converted by the addition mineral metabolism abnormalities observed clinically,
and vascular calcification observed pathologically in di-of alkaline phosphatase) did not inhibit mineralization,
whereas phosphorylated osteopontin did inhibit mineral- alysis patients.
To examine further the role of hyperphosphatemiaization [29]. Therefore, the net effect of osteopontin is
dependent on its state of phosphorylation, suggesting a and vascular calcification observed in dialysis patients,
we analyzed the effects of pooled uremic sera from twopotential control mechanism by which this non-collage-
nous protein may be involved in the calcification of groups of dialysis patients: Those with persistently ele-
vated serum phosphorus levels (6.5 mg/dL; pooledVSMC. In the present study, uremic serum induced min-
eralization, alkaline phosphatase activity, and osteopon- sera level  7.4 mg/dL), and those with serum phos-
phorus in the “normal” target range for dialysis pa-tin expression. However, we did not determine if the os-
teopontin was phosphorylated, nor did we perform serial tients (5.5 mg/dL [34]; pooled sera phosphorus level 
5.5 mg/dL). Using these pooled sera in vitro, we demon-studies in vitro. Thus, it is unclear whether the increased
osteopontin production is to try to enhance or inhibit strated that uremic sera potentiate calcium deposition
in BVSMC. We further demonstrated that both groupsmineralization. Clearly, more work is needed to under-
stand this complex process, but these data support that of uremic sera led to increased expression of osteopontin
in BVSMC. Similar to the exogenous addition of phos-the process is at least partly regulated, even in uremia.
In the present study in BVSMC incubated with FBS phorus in the form of -glycerophosphate, the uremic
serum-induced osteopontin expression is dependent onand phosphorus, in the form of -glycerophosphate, can
induce the expression of osteopontin. This process is both alkaline phosphatase and Na/Pi co-transport. How-
ever, in contrast to the effect observed with -glycero-dependent on alkaline phosphatase activity and Na/Pi
co-transport, as both levamisole (an inhibitor of alkaline phosphate, the induction of uremic serum-induced osteo-
pontin expression was only partially blocked by foscarnet,phosphatase) and foscarnet (an inhibitor of Na/Pi co-trans-
port) completely abolished -glycerophosphate-induced indicating that the mechanism was not completely depen-
dent on Na/Pi co-transport.alkaline phosphatase activity and osteopontin expres-
sion in BVSMC. Although the inhibitors used in the We were unable to demonstrate a difference in osteo-
pontin expression between the two uremic groups: lowcurrent study are specific for alkaline phosphatase and
Na/Pi co-transport, both levamisole and foscarnet may phosphorus (LP) or high phosphorus (HP). One poten-
tial explanation is that cells were treated with 10% uremichave other mechanisms of action. Levamisole can inhibit
Na,K-ATPase [30] and foscarnet can inhibit DNA sera in which the serum, and thus the phosphorus concen-
tration was diluted, bringing the final media concentra-polymerase [31].
To date, three types of Na/Pi co-transporters have tion well below the lower limits of phosphorus (2 mol/L
6.2 mg/dL) previously shown to induce vascular cell calci-been identified [32]. Recently, type III Na/Pi co-trans-
porter was found to be expressed constitutively in human fication in human VSMC in vitro [13], and well below
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